Request information
This is a website for healthcare professionals. Read more.
By sending the contact form, I confirm that I am a healthcare professional.

STERITALC®

STERITALC® consists of talcum which is mined in France and is specifically processed for medical use (talcum pleurodesis).

STERITALC® is suited for all indications of pleurodesis. It is non-soluble and induces permanent pleurodesis. Compared with tetracyclines, talcum is more effective and less painful.

As a rule, for malignant indications 3 to 5 g are used, for treatment of spontaneous pneumothorax 2 g are sufficient in most cases.

A critical side effect of talcum pleurodesis can be ARDS (Acute Respiratory Distress Syndrome). A possible cause of ARDS may be the systemic dissemination of talcum. In some cases, after application in the pleural cavity, talcum was found in other organs (kidneys, spleen, liver), too. The literature assumes that there is a relation between the talcum particle size and the systemic dissemination of talcum: smaller talcum particles appear to disseminate more than larger ones1). The clinical picture also shows the effect of different particle sizes: talcum with a mean particle size below 15 µm induced stronger systemic and pulmonary inflammation reactions than talcum with a mean particle size of 25 µm.

STERITALC®, produced by Novatech, is specifically calibrated to a mean particle size of 25 µm in order to avoid systemic dissemination. Animal3) and clinical studies2) show the lesser systemic dissemination.

A multi-center study showed that STERITALC® with its calibrated particle size can be safely used for pleurodesis of malignant pleural effusions. None of more than 550 patients developed ARDS4). The authors recommend to use no other talcum.

Another cause of ARDS may be a sepsis due to unsterile talcum, or talcum containing endotoxines5). This, too, can be excluded when STERITALC® is used, because STERITALC® is free of endotoxines and comes sterile.

1) Ferrer, CHEST 2002; 122: 1018-1027
2) Maskell, Am .J. Respir. Crit. Care Med. 2004; 170: 377-382
3) Fraticelli, CHEST 2002; 122:1737-1741
4) Janssen, Lancet 2007; 369: 1535-1539
5) Antony, Eur. Respir. J. 2001; 18: 402-419

Three dosage forms

STERITALC® Vial F2, F4

  • For use as a slurry (to be mixed with physiological saline solution; Xylocain may be added)
  • For poudrage application via a thoracoscope / trocar

STERITALC® PF3

  • For direct poudrage application via a thoracoscope / trocar (nebulization by air)
  • No limitations regarding storage and handling
  • Self-contained system – comes in a set with 3 g STERITALC®, a 420 mm cannula as well as a balloon nebulizer

STERITALC® Spray

  • For direct poudrage application via a thoracoscope / trocar (nebulization by aerosol)

Ordering Information

REF

STERITALC®
Description

Quantity of medical talc

Items / box

16903

F2: Vial, 50 ml

2 g

4

16913

F4: Vial, 50 ml

4 g

4

16833

Spray, with cannula 440 mm

3 g

2

16863

PF3: Vial, 10 ml
with balloon and cannula 420 mm
(poudrage kit)

3 g

2 kits

16983

Accessory for 16863:
Vial, 10 ml

3 g

4

Professional References